
Biotech startup raises $107m to advance oncology candidates
Biotech startup EpiBiologics has raised $107 million Series B financing to support its pipeline of novel bispecific antibodies. The financing, co-led by Google Ventures and Johnson & Johnson, will be used to advance candidate EPI-326 into a first-in-human clinical trial for treatment of EGFR-driven lung cancer and head and… Read More

